T1	Participants 80 142	human immunodeficiency virus-infected children and adolescents
T2	Participants 643 770	Forty-one children and youths between 5 months and 21 years with prior NRTI and no prior NNRTI or protease inhibitor experience
T3	Participants 280 330	nucleoside reverse transcription inhibitor (NRTI)-
T4	Participants 2422 2443	HIV-infected children
